Methods of enhancing drug delivery and effectiveness of therapeutic agents

Patent metadata

Field	Value
Publication number	US-10660965-B2
Application number	US-201113073861-A
Country	US
Kind code	B2
Filing date	Mar 28, 2011
Priority date	Mar 29, 2010
Publication date	May 26, 2020
Grant date	May 26, 2020

Abstract

The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.

First claim

What is claimed is:

1. A method of treating a cancer that is highly fibrotic and/or has a dense stroma in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin,
wherein a high stromal caveolin-1 level is used as a basis for selecting the individual to receive treatment,
wherein the high stromal caveolin-1 level is a level that is higher than the median level in a patient population having the cancer,
wherein the cancer is at an advanced stage,
wherein the cancer is a lung cancer,
wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, and
wherein the nanoparticles in the paclitaxel nanoparticle composition comprise paclitaxel coated with albumin.

2. The method of claim 1 , wherein the cancer is a squamous cell carcinoma.

3. The method of claim 1 , wherein the method comprises assessing one or more of the following in the individual prior to administering the paclitaxel nanoparticle composition: (a) the amount of tissue stroma, (b) tissue vascularization, (c) cell/vessel proximity, (d) density of tumor matrix, and (e) expression of stromal cell markers.

4. The method of claim 1 , wherein the nanoparticles in the paclitaxel nanoparticle composition have an average particle size of less than 200 nm.

5. A method of treating a cancer in an individual, comprising administering to the individual:
(a) an effective amount of a composition comprising nanoparticles comprising albumin and paclitaxel, and
(b) an effective amount of a therapeutic agent,
wherein a high stromal caveolin-1 level is used as a basis for selecting the individual to receive treatment,
wherein the high stromal caveolin-1 level is a level that is higher than the median level in a patient population having the cancer,
wherein the cancer is at an advanced stage,
wherein the cancer is lung cancer,
wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, and
wherein the nanoparticles in the paclitaxel nanoparticle composition comprise paclitaxel coated with albumin.

6. The method of claim 5 , comprising determining the stromal caveolin-1 level in the individual prior to the administration of the paclitaxel nanoparticle composition.

7. The method of claim 5 , wherein the cancer is a squamous cell carcinoma.

8. The method of claim 5 , wherein the nanoparticles in the paclitaxel nanoparticle composition have an average particle size of less than 200 nm.

9. The method of claim 5 , wherein the therapeutic agent is selected from the group consisting of: an antimetabolite, a platinum-based agent, and prednisone.

10. The method of claim 5 , wherein the individual is not responsive to the treatment of the composition comprising nanoparticles comprising paclitaxel and the albumin when administered alone.

11. The method of claim 5 , wherein the individual is not responsive to the treatment of the therapeutic agent when administered alone.

12. The method of claim 10 , wherein the individual is not responsive to the treatment of the therapeutic agent when administered alone.

Assignees

• Desai Neil P
• Soon Shiong Patrick
• Abraxis Bioscience Llc

Inventors

• Desai Neil P
• Soon-Shiong Patrick

Classifications

• A61K9/5169 Primary

  Proteins, e.g. albumin, gelatin · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title